Patient screening of Innovation Pharmaceuticals’ phase 1 trial in Jan
Category: #health  By Pankaj Singh  Date: 2019-12-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Patient screening of Innovation Pharmaceuticals’ phase 1 trial in Jan

Innovation pharmaceuticals is gearing for the roll out of patient screening for phase 1 trial in January that will apparently examine the significance of delayed release tablets for oral Brilacidin’s colonic delivery in healthy volunteers which will help in the treatment of Ulcerative Colitis.

A fortnight ago, Innovation Pharmaceuticals received green signal from Medicines and Healthcare products Regulatory Agency of the UK to kick off the Phase 1 trial. Apparently, the study is expected to assess oral Brilacidin’s delivery directly to the colon by using sophisticated delayed-release drug delivery technology pioneered by formulation partner of the company. Nevertheless, the study will also analyze toleration, safety and pharmacokinetics of oral Brilacidin.

Leo Ehrlich, CEO of Innovation Pharmaceuticals expects study to be completed in a short span of time and stated that dosing would lead to a slew of positive results for the company. He went on to add that he was sanguine of the efficacy and safety landscape of Brilacidin in IBD, given the clinical trial held in the past in Ulcerative Proctitis/Ulcerative Proctosigmoiditis.

Ehrlich was quoted expressing confidence pertaining to the commercial future and competitive landscape of oral rinse Brilacidin as a preventive OM drug candidate and the brand value it can bring to the company. The statement came in the wake of apparent aura surrounding the initial public offerings (IPOs) of Monopar Therapeutics and Galera Therapeutics.

He expressed his delight that their out-licensing partner is contemplating trials mid-year 2020. Ehrlich stressed the relevance of efficacious delivery of the drug directly into the colon, which would eventually help in wooing big pharmaceutical companies and would bolster differentiation.

The meeting of investors with pharmaceuticals companies having interest in Brilacidin is set to take place in January during the 2020 J.P Morgan Healthcare conference in San Francisco. Shareholders would be buoyed if a licensing deal for the Brilacidin-OM asset turns into a reality.
 

Source credit:

http://www.ipharminc.com/press-release/2019/12/26/innovation-pharmaceuticals-patient-screening-for-phase-1-trial-of-oral-brilacidin-in-ulcerative-colitis-program-on-track-for-early-january



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...

Amazon to open new fulfillment center with 500 jobs in Coweta County
Amazon to open new fulfillment center with 500 jobs in Coweta County
By Pankaj Singh

Brian Kemp, the 83rd Governor of Georgia, has recently announced that Amazon will be launching a new fulfillment center in Newman, adding 500 full-time jobs at the new facility in Coweta County. Employees in...

Payless emerges from Chapter 11 bankruptcy to reopen U.S. stores
Payless emerges from Chapter 11 bankruptcy to reopen U.S. stores
By Pankaj Singh

Payless ShoeSource has emerged from Chapter 11 bankruptcy for the second time and is planning a comeback after the closure of Brookville distribution center and retail stores in 2019. The company is currently focusing ...